CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

25.02.19		Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry (Businesswire)
10.12.18		Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing (Businesswire)
13.11.18		Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 (Businesswire)
19.09.18		CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board (Businesswire)
18.09.18		Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP (Businesswire)
02.08.18		Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer (Businesswire)
01.08.18		Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 (Businesswire)
27.06.18		Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 (Businesswire)
12.06.18		Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports (Businesswire)
04.06.18		FDA Grants Cellectis IND Approval for UCART22 in B-ALL (Businesswire)
23.05.18		INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
22.05.18		Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
21.05.18		Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
15.05.18		Calyxt Announces Launch of Proposed Follow-On Offering (Businesswire)
10.05.18		Cellectis to Present Data at the 2018 ASGCT Annual Meeting (Businesswire)
07.05.18		Cellectis Reports 1st Quarter 2018 Financial Results (Businesswire)
02.05.18		Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) (Businesswire)
01.05.18		Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome (Businesswire)
11.04.18		Cellectis to Present Data at the 2018 AACR Annual Meeting (Businesswire)
10.04.18		Cellectis Announces Closing of Follow-On Offering (Businesswire)
05.04.18		Cellectis Announces Pricing of Follow-On Offering (Businesswire)
03.04.18		Cellectis Announces Launch of Follow-On Offering (Businesswire)
03.04.18		Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies (Businesswire)
13.03.18		Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor (Businesswire)
12.03.18		Cellectis Reports 4th Quarter and Full Year 2017 Financial Results (Businesswire)
08.03.18		Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting (Businesswire)
13.02.18		Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells (Businesswire)
06.02.18		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
08.01.18		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.01.18		Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT (Businesswire)
13.12.17		Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials (Businesswire)
04.12.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
04.12.17		Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer (Businesswire)
04.12.17		Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development (Businesswire)
20.11.17		Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy (Businesswire)
13.11.17		Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 (Businesswire)
08.11.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.11.17		FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN (Businesswire)
01.11.17		Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting (Businesswire)
01.11.17		Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting (Businesswire)
04.10.17		Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (Businesswire)
04.10.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.09.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
05.09.17		Cellectis to Participate in Upcoming Investor Conferences (Businesswire)
05.09.17		Cellectis Reports Clinical Hold of UCART123 Studies (Businesswire)
17.08.17		Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center (Businesswire)
02.08.17		Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 (Businesswire)
02.08.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
25.07.17		Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering (Businesswire)
24.07.17		Cellectis Granted Patent for CRISPR Use in T-Cells (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

Delivery-Hero-Aktie tiefrot: Delivery-Hero-Tochter Talabat nach deutlichem Kursplus bei Börsenstart unter Ausgabepreis

Ripple fällt auf 2 US-Dollar zurück – Was passiert jetzt?

TeamViewer-Aktie in Rot: TeamViewer mit größtem Zukauf - Übernahme von 1E

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.12.2024 17:01
Kaufwert:	EUR
	Hinzufügen Speichern